Home »
Academic Articles »
C »
A hybrid nanomodulator enables metabolic microenvironment remodeling for potent immunotherapy against lung adenocarcinoma
A hybrid nanomodulator enables metabolic microenvironment remodeling for potent immunotherapy against lung adenocarcinoma
Shuping Wang
(Department of Clinical Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China)
Pengcheng Chen
(Department of Clinical Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China)
Xiaozhen Jing
(Department of Clinical Laboratory Medicine, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China)
Jinglin Zou
(Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials Biology and Dynamic Chemistry, Shanghai Engineering Research Center of Hierarchical Nanomaterials, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China)
Lingxia Li
(Department of Clinical Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China)
Cong Jiang
(Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200092, China)
Nike Qian
(Department of Clinical Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China)
Xufeng Zhang
(Department of Clinical Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China)
Lei Shi
(Department of Clinical Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China)
Yunxia Xu
(Disinfection Supply Room, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China; Corresponding authors.)
Feng He
(Department of Thoracic Surgery, Fuzhou Pulmonary (Chest) Hospital of Fujian No. 8 Beiyuan Road, Cangshan District, Fuzhou City, Fujian Province 350008, China; Corresponding authors.)
Zhengrong Zhong
(Department of Clinical Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Corresponding authors.)
STING agonist-based immunotherapy holds considerable promise for cancer treatment, yet its efficacy against immunologically “cold” tumors such as lung adenocarcinoma (LUAD) remains markedly limited. A major obstacle lies in the highly glycolytic tumor microenvironment (TME), where Warburg effect-driven metabolic competition deprives immune cells of adequate energetic support and thereby compromises their antitumor activity. Herein, we develop a metabolism regulation-based STING-activating hybrid nano-regulator (Que@ZnPDA) for sensitized immunotherapy against LUAD. Upon intravenous administration, Que@ZnPDA undergoes GSH-responsive disassembly in the TME to release quercetin (Que) and Zn 2+ . Que suppresses glycolysis through downregulating MCT4, whereas Zn 2+ inhibits mitochondrial complex IV activity to restrain oxidative phosphorylation, leading to concurrent disruption of energy-supplying pathways in tumor cells. The resulting energy depletion directly impairs tumor cell survival and relieves metabolic pressure within the TME. Meanwhile, Zn 2+ activates the cGAS-STING pathway, while glycolysis inhibition-induced TREX1 downregulation and mitochondrial damage further elevate cGAS expression, thus strengthening STING signaling and promoting cytokine secretion to reverse the immunosuppressive microenvironment. This metabolism regulation-based hybrid nano-regulator provides a promising strategy for LUAD immunotherapy.